Active Ingredient(s):Pertuzumab + Trastuzumab + Hyaluronidase-zzxf FDA Approved: * June 29, 2020 Pharm Company: *GENENTECH INC Category:Cancer
Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer. It contains pertuzumab, trastuzumab, and hyaluronidase–zzxf. It is injected under the skin via subcutaneous injection in the thigh. In the Euro...
* May have multiple approval dates, manufacturers, or labelers.